SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anstrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positve, HER2-Negative Advance Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease